StockWatch
·
Q2 FY-2027 RESULTS · BLUESTARCO

Blue Star Q2 FY27: PAT +25% YoY but Flat Ex-Exceptional as RAC Margins Stay Squeezed

PAT +25.44% YoY · revenue +21% · margins compressing

Q2 FY27 resultsBLUESTARCOBLUE STAR LTD.29 Oct 2026 · 3 min read
Revenue

₹2,930.95 Cr

+21% YoY

PAT (consolidated)

₹123.91 Cr

+25.44% YoY

Net margin

4.2%

+0.1pp YoY

EPS

₹6.03

Blue Star's consolidated PAT rose 25.4% YoY to ₹123.91 Cr on revenue up 21.0% YoY to ₹2,930.95 Cr, but the headline is flattered by a ₹23.02 Cr exceptional gain from the sale of its Medtech business. Strip that out and PBT-before-exceptional items grew just 1.6% YoY (₹134.28 Cr vs ₹132.17 Cr), with adjusted PAT growth around +2% — essentially flat earnings power despite strong topline growth. No formal street consensus specific to this quarter could be located (results were filed same-day); a web search found no Q2 FY27-specific brokerage preview, so vsStreet is unknown rather than assumed.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹2,930.95 Cr-13.2%+21%
Expenses₹2,813.13 Cr-14.1%+22.4%
PAT₹123.91 Cr+20.88%+25.44%
Net margin4.2%+1.2pp+0.1pp
EPS₹6.03+20.8%+25.6%

The margin story is the quarter: consolidated OPM compressed to 6.91% from 7.57% a year ago, and the squeeze is concentrated in the Unitary (room-AC) segment, whose EBIT margin was just 2.31% in Q2 (2.72% for H1) — far below the >6.5% FY27 guidance (aspiring 7-7.5%) management set on last quarter's call. The Electro-mechanical/commercial-AC segment, by contrast, held margin at 6.88% in Q2 (6.83% H1), squarely within its guided 6.5-7% band, so the miss is guidance-specific to RAC, not company-wide. This confirms rather than surprises: management had already been publicly warning that an 8% price hike effective October 1, 2026 would still be insufficient to offset a cumulative ~18% rise in copper, steel and logistics costs since January 2026, with only a fraction of planned hikes passed through due to a delayed summer and competitor pricing pressure.

₹
1,411.231,499.241,587.251,675.261,763.271,67307-2708-1809-0910-0510-2810-29Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,673, up 6.2% over the past month of trading.

₹ Cr
084.81169.63254.44120.82Q1 FY26rev ₹2,982 Cr98.78Q2 FY26rev ₹2,422 Cr80.55Q3 FY26rev ₹2,925 Cr227.18Q4 FY26rev ₹4,072 Cr102.51Q1 FY27rev ₹3,378 Cr123.91Q2 FY27rev ₹2,931 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Beyond the headline

What the summary numbers don't show

₹23.02 Cr exceptional gain from sale of Medtech business by subsidiary Blue Star Engineering & Electronics; H1 exceptional total ₹32.19 Cr also includes a ₹9.17 Cr property-sale gain booked in Q1

What management guided (1 FY-2027 call)
FY27 Segment II EBIT margin >6.5% (aspires 7-7.5%); Segment I 6.5-7%. Data center MEP: ₹3,000 Cr order inflow, ₹1,400 Cr revenue FY27; ₹4,000 Crore revenue by FY29. RAC market 18% CAGR potential over 5-year period.

— This quarter: missed

Segment revenue mix shows where growth came from: Unitary products revenue grew 29.4% YoY to ₹897.66 Cr even as its margin collapsed, while Electro-mechanical/commercial-AC grew 16.3% YoY to ₹1,935.99 Cr at a steady margin. The 13.2% QoQ revenue decline (₹3,377.92 Cr to ₹2,930.95 Cr) is pure AC seasonality — Unitary revenue fell 46.9% QoQ as the summer selling season rolled off — not a demand signal. Standalone PAT of ₹38.24 Cr (vs consolidated ₹123.91 Cr) reflects that the Medtech exceptional gain and most overseas-subsidiary contribution sit outside the standalone entity. Separately, Blue Star's Oman arbitration saw WJT's claims dismissed (Sep 15, 2026) — a legal overhang cleared, though not a P&L item this quarter. The filing carries no fresh disclosure on the data-center MEP pipeline (₹3,000 Cr order inflow / ₹1,400 Cr revenue FY27 targets flagged last quarter), so that guidance remains unverified this print.

  • W1

    FY27 Segment II (Unitary/RAC) EBIT margin guided >6.5% (aspiring 7-7.5%) vs just 2.72% in H1 — watch whether the 8% price hike effective Oct 1, 2026 closes the gap in H2

  • W2

    Management flagged input costs (copper, steel, logistics) up ~18% cumulatively since Jan 2026 with price hikes only partially passed through — watch Q3 commentary on whether the latest hike holds against competitor pricing

  • W3

    Data-center MEP pipeline (₹3,000 Cr order inflow, ₹1,400 Cr revenue FY27 target; ₹4,000 Cr revenue by FY29) was not disclosed in this filing — watch for an update next quarter

Consolidated PBT includes a ₹23.02 Cr exceptional gain (Medtech business sale by subsidiary Blue Star Engineering & Electronics); H1 exceptional total ₹32.19 Cr also folds in a ₹9.17 Cr property-sale gain booked in Q1, which sits in the standalone books. NCI of ₹(0.01) Cr makes period profit (123.91) marginally differ from owners'-attributable profit (123.92). All figures legible, limited-review report unmodified.

Informational and educational content only. Not investment advice.